Accessibility options |
West London NHS Trust > Feedback and involvement > Research > Our studies

Our studies

West London NHS Trust is a research-active Trust, currently involved in over 20 studies across different areas of mental and physical health. 

We actively encourage our staff and service users to become involved in research, so please contact research@westlondon.nhs.uk if you are interested in taking part in any of our studies. Read more about our studies below:

Dementia studies

Delphia

The Delphia research study is looking at how well a new drug called E2027 works for people who have Dementia with Lewy Bodies (DLB).

This type of dementia is caused by abnormal clumps of a protein called Lewy Bodies, in a person’s brain.

The Delphia trial is investigating whether E2027 could help to reduce the symptoms of dementia for people with this condition.  We are looking for people with DLB to participate in this study.

What happens in the study? 

Participants will be enrolled in the study for a maximum of 22 weeks, and during this time will be given either E2027 or a placebo medication (a drug which has no effect on the person taking it).  Participants will be asked to complete a number of medical assessments which will allow us to see whether the medication is working as it should do.

European Prevention of Alzheimer’s Dementia (EPAD)

The Project aims to better understand he factors involved in developing Alzheimer’s dementia and develop new treatments which it’s hoped will prevent Alzheimer’s dementia.

What happens in the study?

Participants will be asked to have a range of physical and psychological tests and assessments over the course of five study visits across four years.

If a participant shows signs of developing Alzheimer’s dementia they may then be asked to join a second study trialling different medications.

NorAD

Currently approved drugs for Alzheimer’s Disease, (the most common cause of dementia), have a very small effect on thinking and quality of life, and most work by increasing levels of acetylcholine, the neurotransmitter most closely linked with memory.  

However there is also clear evidence of dysfunction of the noradrenaline system, which appears to play a particularly important role in general arousal and attention, which are affected soon after memory in Alzheimer’s Disease. 

This trial will look at whether boosting noradrenaline, in addition to standard treatment, will improve attention and more general aspects of thinking in patients with Alzheimer’s Disease.

What happens in the study?

This trial is a randomised controlled trial which means that half the participants will receive a drug called Guanfacine, which has been shown to boost attention and memory in animal studies and in healthy humans, and is licensed for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and half will be given a placebo (a drug which has no effect on the person taking it).

This will help assess whether boosting noradrenaline, in addition to standard treatment, will improve attention and more general aspects of thinking in patients with Alzheimer’s Disease.

Mental Health Studies

Sleep and psychotic features

People who suffer from mental health disorders often have difficulties regulating their mood and emotions.  They are also often troubled with disrupted sleeping patterns which can range from being unable to fall asleep, sleeping at the wrong time of day, or having excessive sleepiness.

Poor sleep also predicts a ‘relapse’ or sudden worsening of symptoms.  We are interested in finding out whether there is an association between the difficulty of regulating mood and of sleep patterns.

This study has been designed to investigate the relationship between sleep and mood in people who have been referred to NHS mental health services, to understand if sleep problems are present in these people.